6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy

4.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy

Immuno-oncology has revolutionized cancer management by leveraging the host immune system to recognize and eradicate tumor cells. Unlike cytotoxic chemotherapy or targeted therapies that act directly on tumor cell machinery, immunotherapies target immune regulatory pathways or genetically re-engineer immune effector cells. For the Advanced Oncology Certified Nurse Practitioner (AOCNP®), an in-depth understanding of immune checkpoint blockade, the spectrum and management of immune-related adverse events (irAEs), and the specialized protocols for Chimeric Antigen Receptor (CAR) T-cell therapy—including toxicities like Cytokine Release Syndrome (CRS) and neurotoxicity—is critical for safe patient care.

---

1. Immune Checkpoint Inhibitor (ICI) Biology & Targets

Tumor cells evade host immune surveillance by exploiting endogenous immune checkpoints—surface receptors that normally maintain peripheral self-tolerance and limit collateral tissue damage during inflammatory responses. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block these inhibitory interactions, restoring cytotoxic T-lymphocyte activation and anti-tumor activity.

Core Checkpoint Receptor Pathways

• CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Blockade: CTLA-4 regulates T-cell activation early within lymph nodes during the priming phase. It competes with the costimulatory receptor CD28 for binding to B7-1 (CD80) and B7-2 (CD86) ligands on antigen-presenting cells (APCs). Ipilimumab (anti-CTLA-4 mAb) blocks CTLA-4, allowing unrestrained T-cell proliferation and priming. Because CTLA-4 acts broadly in systemic immune priming, ipilimumab carries a higher incidence of severe immune toxicities.
• PD-1 (Programmed Cell Death Protein 1) Blockade: PD-1 operates primarily in peripheral tissues during the effector phase of T-cell responses. Activated T-cells express PD-1; when bound to its ligands (PD-L1 or PD-L2) expressed on tumor cells or tumor-infiltrating macrophages, PD-1 transmits an inhibitory signal that induces T-cell exhaustion and unresponsiveness. Monoclonal antibodies targeting PD-1 (pembrolizumab, nivolumab, cemiplimab) prevent ligand binding and re-energize exhausted tumor-infiltrating lymphocytes.
• PD-L1 Blockade: Monoclonal antibodies targeting the PD-L1 ligand on tumor cells (atezolizumab, durvalumab, avelumab) selectively disrupt the PD-1/PD-L1 interaction while preserving PD-1 binding to PD-L2, potentially reducing specific inflammatory side effects.

---

2. Clinical Management of Immune-Related Adverse Events (irAEs)

Disrupting immune checkpoint pathways leads to a distinct spectrum of autoimmune-like toxicities termed immune-related adverse events (irAEs). irAEs can affect any organ system, most commonly appearing within 2 to 16 weeks of initiating treatment, though delayed onset can occur months after drug discontinuation.

Common Terminology Criteria for Adverse Events (CTCAE) Management Algorithm

1. Grade 1 (Mild; asymptomatic or mild symptoms): Continue ICI with close clinical and laboratory monitoring (except for cardiac, neurologic, or hematologic toxicities, which prompt immediate hold).
2. Grade 2 (Moderate; minimal non-invasive intervention indicated): Hold ICI. Initiate oral systemic corticosteroids (prednisone 0.5–1 mg/kg/day or equivalent). Upon symptom improvement to Grade ≤ 1, taper steroids slowly over 4 to 6 weeks before considering ICI resumption.
3. Grade 3–4 (Severe or life-threatening): Permanently discontinue ICI (in most cases). Immediately hospitalize patient and initiate high-dose corticosteroids (intravenous methylprednisolone 1–2 mg/kg/day or equivalent).
4. Steroid-Refractory irAEs: If no clinical improvement occurs within 48 to 72 hours of high-dose corticosteroids, initiate second-line immunosuppressive agents:
   • Refractory Colitis: Infliximab (5 mg/kg IV) or vedolizumab (300 mg IV).
   • Refractory Hepatitis: Mycophenolate mofetil (500–1000 mg PO/IV BID). Note: Infliximab is contraindicated in severe hepatic injury due to hepatotoxicity risk.
   • Refractory Myocarditis: High-dose pulse methylprednisolone (1000 mg IV daily for 3 days) plus antithymocyte globulin (ATG), infliximab, or abatacept.

---

3. Chimeric Antigen Receptor (CAR) T-Cell Therapy Architecture

CAR T-cell therapy represents an advanced cellular immunotherapy wherein autologous T-cells are harvested via leukapheresis, genetically transduced using a viral vector to express a synthetic Chimeric Antigen Receptor (CAR), expanded ex vivo, and re-infused into the patient following lymphodepleting conditioning chemotherapy.

CAR Structure Components

• Extracellular Antigen-Binding Domain: Single-chain variable fragment (scFv) derived from a monoclonal antibody that targets specific surface antigens in a major histocompatibility complex (MHC)-independent manner.
• Transmembrane Domain: Anchors the receptor to the T-cell membrane.
• Intracellular Signaling Domain: Contains a primary T-cell activation domain (CD3-zeta) combined with one or more costimulatory domains (CD28 or 4-1BB / CD137). Costimulatory domains enhance T-cell proliferation, persistent survival, and memory formation in vivo.

FDA-Approved Targets

• CD19-Directed CAR T-Cells (tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel): Indicated for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and follicular lymphoma.
• BCMA (B-Cell Maturation Antigen)-Directed CAR T-Cells (idecabtagene vicleucel, ciltacabtagene autoleucel): Indicated for relapsed/refractory multiple myeloma.

---

4. ASTCT Protocols for Acute CAR T-Cell Complications

Prior to CAR T-cell infusion, patients receive lymphodepleting chemotherapy (typically fludarabine 30 mg/m² daily plus cyclophosphamide 500 mg/m² daily for 3 days) to eradicate endogenous lymphocytes and create a favorable cytokine niche (elevated IL-7, IL-15) for CAR T expansion. Systemic toxicities managed under American Society for Transplantation and Cellular Therapy (ASTCT) consensus guidelines include:

A. Cytokine Release Syndrome (CRS)

CRS is a systemic inflammatory response triggered by massive CAR T-cell activation and proliferation, resulting in excessive production of pro-inflammatory cytokines, predominantly interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).

B. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ICANS results from cytokine-mediated blood-brain barrier disruption and microglial activation. Early signs include dysgraphia (inability to write a standard sentence), expressive aphasia, confusion, tremors, motor weakness, and cerebral edema.

• Diagnostic Assessment: Perform the 10-point Immune Effector Cell Encephalopathy (ICE) score screening every 8 hours (evaluating orientation, naming, following commands, writing, and concentration).
• Grade 1 ICANS (ICE score 7–9): Supportive care; hold sedatives; perform neurology consult and non-contrast head CT.
• Grade 2 ICANS (ICE score 3–6): Initiate dexamethasone 10 mg IV every 6 to 12 hours. Note: Tocilizumab does not effectively cross the blood-brain barrier and is NOT indicated for isolated ICANS unless concurrent CRS is present.
• Grade 3–4 ICANS (ICE score 0–2, seizures, or cerebral edema): Administer dexamethasone 20 mg IV every 6 hours or high-dose IV methylprednisolone (1000 mg/day). Manage status epilepticus with levetiracetam or lorazepam.